Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 63618 | 8.15 |
09:34 ET | 9168 | 8.21 |
09:36 ET | 9572 | 8.27 |
09:38 ET | 17650 | 8.358 |
09:39 ET | 123920 | 8.64 |
09:41 ET | 38574 | 8.63 |
09:43 ET | 186212 | 8.49 |
09:45 ET | 51499 | 8.3 |
09:48 ET | 145064 | 8.04 |
09:50 ET | 32103 | 8.0417 |
09:52 ET | 18714 | 8.0348 |
09:54 ET | 8968 | 8.15 |
09:56 ET | 6755 | 8.18 |
09:57 ET | 9299 | 8.3 |
09:59 ET | 8603 | 8.33 |
10:01 ET | 6524 | 8.175 |
10:03 ET | 12540 | 8.15 |
10:06 ET | 2453 | 8.13 |
10:08 ET | 8936 | 8.06 |
10:10 ET | 3582 | 8.04 |
10:12 ET | 5445 | 8.08 |
10:14 ET | 8128 | 8.02 |
10:15 ET | 18120 | 7.9502 |
10:17 ET | 16379 | 7.91 |
10:19 ET | 34508 | 7.865 |
10:21 ET | 14410 | 7.865 |
10:24 ET | 13031 | 7.83 |
10:26 ET | 13186 | 7.8399 |
10:28 ET | 30887 | 7.895 |
10:30 ET | 11303 | 7.92 |
10:32 ET | 18675 | 7.96 |
10:33 ET | 22048 | 7.95 |
10:35 ET | 16807 | 7.96 |
10:37 ET | 2881 | 8.0196 |
10:39 ET | 4585 | 7.98 |
10:42 ET | 28515 | 7.86 |
10:44 ET | 5969 | 7.92 |
10:46 ET | 6308 | 7.88 |
10:48 ET | 10429 | 7.83 |
10:50 ET | 36486 | 7.85 |
10:51 ET | 5788 | 7.86 |
10:53 ET | 4588 | 7.82 |
10:55 ET | 9406 | 7.83 |
10:57 ET | 4981 | 7.81 |
11:00 ET | 8451 | 7.89 |
11:02 ET | 2789 | 7.89 |
11:04 ET | 9347 | 7.8399 |
11:06 ET | 54886 | 7.77 |
11:08 ET | 9265 | 7.77 |
11:09 ET | 4725 | 7.7666 |
11:11 ET | 10776 | 7.755 |
11:13 ET | 4182 | 7.775 |
11:15 ET | 7618 | 7.78 |
11:18 ET | 9050 | 7.81 |
11:20 ET | 5520 | 7.78 |
11:22 ET | 14605 | 7.81 |
11:24 ET | 36841 | 7.78 |
11:26 ET | 5532 | 7.76 |
11:27 ET | 1497 | 7.7601 |
11:29 ET | 8708 | 7.755 |
11:31 ET | 10095 | 7.765 |
11:33 ET | 938 | 7.7787 |
11:36 ET | 89377 | 7.69 |
11:38 ET | 44847 | 7.64 |
11:40 ET | 9481 | 7.71 |
11:42 ET | 8421 | 7.65 |
11:44 ET | 1993 | 7.66 |
11:45 ET | 613 | 7.655 |
11:47 ET | 8258 | 7.635 |
11:49 ET | 3230 | 7.635 |
11:51 ET | 73836 | 7.67 |
11:54 ET | 1900 | 7.7 |
11:56 ET | 61002 | 7.675 |
11:58 ET | 4756 | 7.7 |
12:00 ET | 31220 | 7.669 |
12:02 ET | 5468 | 7.66 |
12:03 ET | 12543 | 7.73 |
12:05 ET | 2897 | 7.68 |
12:07 ET | 2926 | 7.686 |
12:09 ET | 7152 | 7.65 |
12:12 ET | 4000 | 7.635 |
12:14 ET | 9821 | 7.68 |
12:16 ET | 7153 | 7.68 |
12:18 ET | 9769 | 7.69 |
12:20 ET | 24076 | 7.695 |
12:21 ET | 7805 | 7.67 |
12:23 ET | 8324 | 7.68 |
12:25 ET | 6980 | 7.695 |
12:27 ET | 3459 | 7.67 |
12:30 ET | 5831 | 7.7 |
12:32 ET | 4184 | 7.7265 |
12:34 ET | 8439 | 7.73 |
12:36 ET | 6134 | 7.715 |
12:38 ET | 10106 | 7.67 |
12:39 ET | 1782 | 7.67 |
12:41 ET | 2359 | 7.69 |
12:43 ET | 1500 | 7.675 |
12:45 ET | 12481 | 7.68 |
12:48 ET | 3440 | 7.75 |
12:50 ET | 5083 | 7.72 |
12:52 ET | 1540 | 7.69 |
12:54 ET | 5950 | 7.7 |
12:56 ET | 1304 | 7.6917 |
12:57 ET | 2100 | 7.7 |
12:59 ET | 4560 | 7.695 |
01:01 ET | 5238 | 7.715 |
01:03 ET | 5438 | 7.72 |
01:06 ET | 3466 | 7.735 |
01:08 ET | 8589 | 7.716 |
01:10 ET | 2755 | 7.71 |
01:12 ET | 6412 | 7.725 |
01:14 ET | 37183 | 7.65 |
01:15 ET | 8705 | 7.65 |
01:17 ET | 921 | 7.63 |
01:19 ET | 1861 | 7.628 |
01:21 ET | 9735 | 7.6194 |
01:24 ET | 6235 | 7.62 |
01:26 ET | 9106 | 7.67 |
01:28 ET | 4287 | 7.71 |
01:30 ET | 18598 | 7.72 |
01:32 ET | 29259 | 7.72 |
01:33 ET | 2971 | 7.71 |
01:35 ET | 13702 | 7.775 |
01:37 ET | 11430 | 7.76 |
01:39 ET | 2470 | 7.72 |
01:42 ET | 19868 | 7.75 |
01:44 ET | 1547 | 7.77 |
01:46 ET | 4781 | 7.77 |
01:48 ET | 6910 | 7.76 |
01:50 ET | 300 | 7.76 |
01:51 ET | 3219 | 7.78 |
01:53 ET | 4970 | 7.79 |
01:55 ET | 7469 | 7.785 |
01:57 ET | 14002 | 7.8 |
02:00 ET | 3209 | 7.78 |
02:02 ET | 7769 | 7.82 |
02:04 ET | 3302 | 7.82 |
02:06 ET | 2527 | 7.83 |
02:08 ET | 10702 | 7.8283 |
02:09 ET | 13194 | 7.861 |
02:11 ET | 4131 | 7.87 |
02:13 ET | 5290 | 7.86 |
02:15 ET | 5121 | 7.86 |
02:18 ET | 12351 | 7.86 |
02:20 ET | 12979 | 7.86 |
02:22 ET | 3863 | 7.85 |
02:24 ET | 23476 | 7.85 |
02:26 ET | 3612 | 7.85 |
02:27 ET | 13801 | 7.865 |
02:29 ET | 9233 | 7.815 |
02:31 ET | 6216 | 7.84 |
02:33 ET | 862 | 7.83 |
02:36 ET | 1338 | 7.83 |
02:38 ET | 11781 | 7.8348 |
02:40 ET | 3692 | 7.83 |
02:42 ET | 3064 | 7.825 |
02:44 ET | 3314 | 7.825 |
02:45 ET | 3346 | 7.811 |
02:47 ET | 11872 | 7.81 |
02:49 ET | 9985 | 7.825 |
02:51 ET | 2349 | 7.82 |
02:54 ET | 7168 | 7.83 |
02:56 ET | 5167 | 7.835 |
02:58 ET | 6761 | 7.815 |
03:00 ET | 3928 | 7.81 |
03:02 ET | 12996 | 7.86 |
03:03 ET | 6063 | 7.88 |
03:05 ET | 11044 | 7.92 |
03:07 ET | 8050 | 7.926 |
03:09 ET | 1213 | 7.915 |
03:12 ET | 16984 | 7.941 |
03:14 ET | 4236 | 7.945 |
03:16 ET | 5547 | 7.915 |
03:18 ET | 3409 | 7.925 |
03:20 ET | 2985 | 7.915 |
03:21 ET | 4861 | 7.945 |
03:23 ET | 26362 | 7.925 |
03:25 ET | 9221 | 7.935 |
03:27 ET | 10131 | 7.91 |
03:30 ET | 12103 | 7.905 |
03:32 ET | 4661 | 7.92 |
03:34 ET | 7445 | 7.91 |
03:36 ET | 11459 | 7.92 |
03:38 ET | 5186 | 7.915 |
03:39 ET | 1461 | 7.915 |
03:41 ET | 15949 | 7.949 |
03:43 ET | 10083 | 7.92 |
03:45 ET | 12968 | 7.94 |
03:48 ET | 18051 | 7.91 |
03:50 ET | 11642 | 7.89 |
03:52 ET | 28099 | 7.92 |
03:54 ET | 16947 | 7.945 |
03:56 ET | 22833 | 7.955 |
03:57 ET | 54096 | 7.915 |
03:59 ET | 320668 | 7.9 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 5.9B | -47.7x | --- |
Madrigal Pharmaceuticals Inc | 5.9B | -12.0x | --- |
Viking Therapeutics Inc | 5.7B | -55.9x | --- |
Cytokinetics Inc | 6.3B | -9.8x | --- |
Revolution Medicines Inc | 6.4B | -9.9x | --- |
BridgeBio Pharma Inc | 5.2B | -8.4x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.9B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.96 |
EPS | $-0.17 |
Book Value | $0.11 |
P/E Ratio | -47.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.